A New Approach

Dr. Dale Bredesen and Dr. David Perlmutter have defined a new path for physicians to treat individuals diagnosed with Alzheimer’s Disease and cognitive decline. Dr. Perlmutter’s best seller book, “Grain Brain”, first spoke of cognitive decline as a type of insulin abnormality of the brain that he refers to as type 3 diabetes. Dr. Dale Bredesen as a professor at UCLA went further in his research and has created the only program that has shown to be successful in preventing the advancement of Alzheimer’s Disease and cognitive decline.

Dr. Bredesen’s best selling book, “The End of Alzheimer’s”, describes causative or contributing factors and treatment programs that are individualized based upon several diagnostic and laboratory testing results.

A recently published article in The Journal of Internal Medicine, “ Advances in the Prevention of Alzheimer’s Disease and Dementia”
“……the most common cognitive impairments in old age probably have mixed etiologies and different pathologies suggesting that combined multi domain preventative interventions targeting several risk factors simultaneously have the highest likelihood of being effective.”

This article suggests that there may be several factors developed over ones lifetime that may cause and or contribute to Alzheimer’s Disease and cognitive decline and treating these issues will produce the best results.

The current treatment used in conventional medicine is using pharmaceutical drugs to attack the amyloid plaques seen in the brain scans of Alzheimer patients. Of the 18 FDA approved drugs used to treat Alzheimer patients, none have successfully helped and unfortunately may contribute to increasing cognitive decline.

If a family member has been diagnosed with AD or another form of cognitive decline it is important to consider an evaluation. The pathological changes seen on brain imagining studies are likely to appear 20 to 25 years prior to any symptoms and earlier detection is favorable to further progression.

to the nations Alzheimer’s Association website,, “….the amyloid plaques seen in Alzheimer patients can occur 20-25 years before any symptoms of cognitive decline.”

This is very important to recognize because if an individual is diagnosed with Alzheimer’s disease, there offspring may posses genetic risk factors. Early evaluation gives one the best opportunity for a favorable outcome or prevention.

Again, from the Journal of Internal Medicine, “…. the overall goal of primary prevention is to reduce the incidence of disease by intervening before the disease onset.”

Alzheimer’s disease is 2X more common in women than men.
Alzheimer’s disease is 4X more common in women than breast cancer.

Genetic – APOE4, MHTF-r, Presenilin
Significant dental history or amalgams
Type I or type2 diabetes
Herpes virus
Toxic or mold exposure
Hormone imbalance
Omega deficiency or imbalance
History of concussion

Dr. Rudack has been certified as a Bredesen ReCode practitioner.
Please visit the home page of for additional information on the ReCode program.

If you would like to schedule a functional medicine consult with Dr. Rudack, call our office at 702-362-0336.
If you have questions concerning this article email us at

Leave a Reply

Your email address will not be published. Required fields are marked *